Form D - Notice of Exempt Offering of Securities:
SEC Accession No. 0002049495-25-000001
Filing Date
2025-06-25
Accepted
2025-06-24 17:31:42
Documents
1
Effectiveness Date
2025-06-25
Items
Item 06c:
Item 3C: Investment Company Act Section 3(c)
Item 3C.7: Section 3(c)(7)

Document Format Files

Seq Description Document Type Size
1 primary_doc.html D  
1 primary_doc.xml D 11569
  Complete submission text file 0002049495-25-000001.txt   12801
Mailing Address 1001 PENNSYLVANIA AVENUE, NW SUITE 220 SOUTH WASHINGTON DC 20004
Business Address 1001 PENNSYLVANIA AVENUE, NW SUITE 220 SOUTH WASHINGTON DC 20004 202-729-5626
Abingworth Clinical Co-Development Fund 3 LP (Filer) CIK: 0002049495 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: D | Act: 33 | File No.: 021-549752 | Film No.: 251070252